Oral Antidiabetic Agents refer to the oral drugs used to treat type 2 diabetes in patients who uncontrolled by diet and exercise. Currently, there are five distinct classes of hypoglycemic agents available include sulfonylureas, meglitinides, biguanides, thiazolidinediones and alpha-glucosidase inhibitors.
This report contains market size and forecasts of Oral Antidiabetic Agents in Global, including the following market information:
Global Oral Antidiabetic Agents Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Oral Antidiabetic Agents market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Sulfonylureas Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Oral Antidiabetic Agents include Novo Nordisk, Eli Lilly, Sanofi, Roche, Teva, AstraZeneca, Wockhardt UK, Merck and Pfizer and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Oral Antidiabetic Agents companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oral Antidiabetic Agents Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Oral Antidiabetic Agents Market Segment Percentages, by Type, 2021 (%)
Sulfonylureas
Meglitinides
Biguanides
Thiazolidinediones
Alpha-glucosidase Inhibitors
Global Oral Antidiabetic Agents Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Oral Antidiabetic Agents Market Segment Percentages, by Application, 2021 (%)
Home Use
Medical Institutions
Others
Global Oral Antidiabetic Agents Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Oral Antidiabetic Agents Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Oral Antidiabetic Agents revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Oral Antidiabetic Agents revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novo Nordisk
Eli Lilly
Sanofi
Roche
Teva
AstraZeneca
Wockhardt UK
Merck
Pfizer
Cipla